Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age

Item Type:	Article
Title:	Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age
Creators Name:	Nowek, K. and Sun, S.M. and Dijkstra, M.K. and Bullinger, L. and Döhner, H. and Erkeland, S.J. and Löwenberg, B. and Jongen-Lavrencic, M.
Abstract:	In double-stranded miRNA/miRNA* duplexes, one of the strands represents an active miRNA, whereas another, known as a passenger strand (miRNA), is typically degraded. MiR-9 is not detectable in normal myeloid cells. Here we show that miR-9* is expressed in 59% of acute myeloid leukemia (AML) cases and we investigate its clinical impact in 567 adults with de novo AML (age⩽60 years). AML cases with detectable miR-9* included a lower percentage of cases with favorable risk (P<0.001) as compared with those with no detectable miR-9. High levels of miR-9 expression independently predicted for higher complete remission (odds ratio=1.28, P=0.013) and better event-free survival (EFS) (hazard ratio (HR)=0.86, P=0.001), relapse-free survival (RFS) (HR=0.84, P=0.008) and overall survival (OS) (HR=0.86, P=0.002). Among the subgroup of adverse risk patients, high miR-9* expressers had strikingly longer median survival than low miR-9* expressers (EFS: 16 vs 5 months, P=0.020; RFS: 12 vs 4, P=0.060; OS: 23 vs 8, P=0.021). Comparative transcriptome analysis suggests that miR-9* regulates genes involved in leukemogenesis, for example, MN1 and MLLT3. This is the first report showing that an miRNA* has prognostic value in AML.
Keywords:	MicroRNAs, Middle Aged, Myeloid Acute Leukemia
Source:	Leukemia
ISSN:	0887-6924
Publisher:	Nature Publishing Group
Volume:	30
Number:	2
Page Range:	303-9
Date:	February 2016
Official Publication:	https://doi.org/10.1038/leu.2015.282
PubMed:	View item in PubMed

Repository Staff Only: item control page